)
BioAge Labs (BIOA) investor relations material
BioAge Labs Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Platform and strategy
Focuses on developing therapies for metabolic diseases by harnessing human aging biology and large-scale molecular data sets, with over 150 million data points and 25,000+ profiles tracked for 50+ years.
Validated discovery platform with ongoing pharma collaborations, including Novartis and Lilly, to identify novel drug targets related to exercise and healthy aging.
Supported by a leadership team with extensive biopharma experience and a strong board, including former CEOs and managing partners from leading pharma and investment firms.
Lead program: BGE-102 (NLRP3 inhibitor)
BGE-102 is an oral, brain-penetrant NLRP3 inhibitor with a unique, patented binding site and novel mechanism, showing best-in-class potency and safety in Phase 1 trials.
Demonstrated >90% suppression of IL-1β and 86% reduction in hsCRP in obese subjects, with 93% achieving normalized hsCRP (<2 mg/L), aligning with injectable anti-inflammatories.
Well-tolerated with only mild/moderate, self-limited adverse events and a wide safety margin.
Strong intellectual property position with composition of matter protection through 2045.
Clinical development and results
Phase 1 trials included healthy volunteers and obese participants, showing dose-proportional pharmacokinetics and sustained pharmacodynamic effects.
In obese cohorts, BGE-102 led to 86% reduction in hsCRP, 44-62% reduction in IL-6, 30% reduction in fibrinogen, and 93% suppression of IL-1β at trough.
Achieved therapeutic concentrations in CSF, supporting potential for CNS indications.
Planned Phase 2a proof-of-concept in obesity and cardiovascular risk, with endpoints including hsCRP, metabolic parameters, and imaging.
- TimeTickerHeadlineOpen
- 5 FebWEX
Q4 2025 revenue and EPS grew strongly, with 2026 guidance projecting continued momentum. - 5 FebCLFD
FY25 sales rose 20% to $150.1M, with improved margins and strong growth outlook for FY26. - 5 FebMAA
Q4 and 2025 results met expectations; 2026 outlook sees modest growth and easing supply. - 5 FebGL
Earnings and premium growth drive higher 2026 guidance and continued share repurchases. - 5 FebABX
Record earnings, strong cash flow, and North America gold IPO plans drive 2025 results. - 5 FebDG
Record free cash flow and broad-based earnings growth drive strong 2025 results and positive 2026 outlook. - 5 FebMOD
Q3 FY26 sales up 31%, strong data center growth, pension charge led to net loss, major spin-off announced. - 5 FebAPOLLOTYRE
Record revenue, profit growth, major expansion, and improved financial metrics in Q3 FY26. - 5 FebCMI
Record 2025 results, $458M Accelera charges, and 2026 growth led by data center power. - 5 FebHP
EBITDA $230M, $1.02B revenue, net loss $97M, $260M debt repaid, strong tech rollout.
Next BioAge Labs earnings date
Next BioAge Labs earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)